Compare prices and buy Cartalax from 18 research peptide vendors - also called suppliers or sources. Updated daily.
A synthetic tripeptide, Ala-Glu-Asp (AED, C12H19N3O8), from Vladimir Khavinson's short-peptide program at the Saint Petersburg Institute of Bioregulation and Gerontology, where it also carries the laboratory code T-31. Its developers' patent describes it as a regulator of bone and cartilage metabolism, and their published studies are cell-culture and rat experiments on chondrocytes, stem cells, skin fibroblasts and kidney tissue. No registered clinical trial has tested it, and it is not FDA-approved.
For research purposes only. Not medical advice.
Cartalax is a synthetic short peptide from Vladimir Khavinson's bioregulator program at the Saint Petersburg Institute of Bioregulation and Gerontology, the program that also produced Epitalon. Its developers assign it to cartilage and bone, and their papers also use the laboratory code T-31. The rest of the family is in Longevity and Bioregulators.
It is the tripeptide Ala-Glu-Asp, written AED, with the formula C12H19N3O8. The developers' Russian patent claims exactly that sequence, and the National Library of Medicine's MeSH vocabulary files cartalax and T-31 as synonyms of alanyl-glutamyl-aspartic acid. The tetrapeptide Ala-Glu-Asp-Leu, sometimes attributed to Cartalax, is Bronchogen, a different Khavinson peptide assigned to bronchial tissue.
The cartilage claim is set out in a Russian patent filed in 2006 by the company SIA Peptides, with Khavinson as first-named inventor, which describes the peptide as normalizing metabolism in bone and cartilage tissue. Its worked examples are toxicity studies in rodents, a study of calcitonin-producing thyroid cells in rats whose pineal gland had been removed, and fragments of rat femoral cartilage in culture, where treated explants grew a larger zone of outgrowth than controls.
A 2023 review from the same institute adds that a polypeptide complex the group extracts from animal cartilage contains the tripeptide Ala-Glu-Asp among its short peptides (Linkova and colleagues, International Journal of Molecular Sciences).
Everything published on the peptide is preclinical, and every paper found includes Khavinson or colleagues from his institute among its authors.
The group's proposed mechanism for its short peptides is that they enter the cell nucleus and bind DNA to change gene expression. For this peptide that rests on computer modelling of DNA binding in a 2014 kidney-cell study (Khavinson, Advances in Gerontology), and the papers name no receptor for it.
The only human data found is the patent's last example: 29 patients with knee osteoarthritis, randomly split into a treated group and a 12-patient saline group. It reports less pain and better joint mobility in 54.5 to 62.7 percent of treated cases and no significant change on X-ray. It reports no outcome for the saline group and no statistical test, does not describe blinding, and PeptideScouter found no peer-reviewed publication of it.
PeptideScouter found no US regulatory record for Cartalax. As of October 20, 2026, it appears in none of these:
A tripeptide. The Russian patent its developers filed in 2006 claims the sequence H-Ala-Glu-Asp-OH, formula C12H19N3O8, and their later reviews list Cartalax as AED, the one-letter code for Ala-Glu-Asp. The tetrapeptide Ala-Glu-Asp-Leu, sometimes attributed to Cartalax, is Bronchogen, a different peptide from the same research program that its developers assign to bronchial tissue. Ala-Glu-Asp-Lys, the other tetrapeptide attributed to it, appears in no paper indexed in PubMed. A certificate of analysis whose mass-spectrometry result fits a molecular weight of about 333 is consistent with the tripeptide.
Not in any registered or peer-reviewed trial that PeptideScouter could find. ClinicalTrials.gov lists no study of it as of October 2026. The only human data is an example in the developers' 2006 Russian patent, which describes 29 patients with knee osteoarthritis, 12 of them given saline, and reports less pain and better joint mobility in 54.5 to 62.7 percent of treated cases with no significant change on X-ray. The patent gives no result for the saline group, no statistical comparison and no blinding. The rest of the published work is cell-culture and animal research from the developers' own institute.
It has none. As of October 20, 2026, Cartalax does not appear in Drugs@FDA, in either table of FDA's Category 2 list of bulk drug substances raising significant safety risks, in FDA's lists of substances nominated for compounding under Sections 503A and 503B, or among the substances FDA named for its July 2026 and next Pharmacy Compounding Advisory Committee meetings. FDA's substance registry has no record of it, ClinicalTrials.gov lists no study, and no FDA warning letter names it. None of these absences is a finding about safety in either direction.
Because some belong to a different molecule. CAS 205640-90-0, printed on some product pages, registers orexin A, a 33-residue neuropeptide, and one vendor page on PeptideScouter's index prints it beside a formula and a PubChem record for a three-residue peptide. PubChem's record for the tripeptide lists 85806-95-7, but only two reagent suppliers deposited that number and no reference registry such as MeSH, ChEBI or FDA's substance registry carries it. PeptideScouter therefore lists no CAS number for Cartalax.
Cartalax is sold by 18 research peptide vendors indexed on PeptideScouter, with 24 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
16 of the 18 indexed vendors currently have Cartalax in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Studz Peptides currently lists Cartalax at $2.10/mg, the lowest listed price across 18 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $1.89/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 18 vendors listing Cartalax publish a PeptideScouter code, worth 5% to 20% off. Applied, the lowest effective price falls from $1.99/mg listed to $1.89/mg at Studz Peptides. Each vendor's code is shown beside its price in the table above.
Cartalax ranges from $1.99/mg to $5.80/mg across 24 listings from 18 research peptide vendors, normalized to USD per milligram and refreshed daily.
18 research peptide vendors currently list Cartalax on PeptideScouter, with 16 in stock right now. We track 24 listings across size and kit variants.
